The pulmonary arterial pressure (PAP) sensor is read by an external body-worn portable reader the size of a smartphone, and allows the continuous monitoring of the pulmonary arterial pressure during daily activity.
It is hoped it will allow doctors to spot signals that existing technologies miss, further improving management of the condition, reducing hospitalisations and mortality rate.
Cardian has recently received £1.5m seed investment from Touchstone Innovations.
The underlying technology was developed by the company’s co-founders Dr Christopher McLeod, Dr Mohammad Reza Bahmanyar, and Dr Longfang Zou of the Institute of Biomedical Engineering and the Department of Electrical and Electronic Engineering at Imperial College.
Following theinvestment, Innovations will hold a 53.7% interest in the Company, comprising a combination of founders equity and 27.3% derived from investment.
Dani Bach, director of healthcare ventures, Touchstone Innovations, writes:
“This is a classic Imperial spin-out. The formation of Cardian capitalises on more than a decade of research from Chris McLeod’s lab within the Department of Electrical and Electronic Engineering at Imperial College.
“We are assembling a strong management team to commercialise this compelling technology, which combined with the expertise of the founding academics, gives us a great opportunity to help to create a new company that could significantly impact the lives of millions of sufferers of cardiac failure.”